Testing USP5 ZnF-UBD analogues with a Displacement Assay and SPR

20 commercial analogues from the Enamine REAL database were screened against the USP5 zinc finger ubiquitin-binding domain (ZnF-UBD) using a displacement assay and the binding potency of best displacing compounds was assessed with a surface plasmon resonance (SPR) assayFunding acknowledgement: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome